Market Overview

Benzinga's Top Upgrades, Downgrades For November 12, 2019

Share:

Upgrades

  • Keefe, Bruyette & Woods changed the rating for Argo Group International Holdings Ltd (NYSE: ARGO) from Market Perform to Outperform. In the third quarter, Argo Gr Intl Hldgs showed an EPS of ($0.44), compared to ($1.12) from the year-ago quarter. The current market cap for Argo Gr Intl Hldgs is at $2.1 billion. The stock has a 52-week-high of $78.57 and a 52-week-low of $60.36. Argo Gr Intl Hldgs's stock last closed at $61.39 per share.
  • Oppenheimer upgraded the stock for CRISPR Therapeutics AG (NASDAQ: CRSP) from Perform to Outperform. For the third quarter, CRISPR Therapeutics had an EPS of $2.40, compared to year-ago quarter EPS of ($1.07). The current market cap for CRISPR Therapeutics is at $2.2 billion. The stock has a 52-week-high of $53.90 and a 52-week-low of $22.22. CRISPR Therapeutics's stock last closed at $50.91 per share.
  • Goldman Sachs upgraded the stock for CrowdStrike Holdings Inc (NASDAQ: CRWD) from Sell to Neutral. CrowdStrike Holdings earned ($0.18) in the second quarter. CrowdStrike Holdings's market cap stands at $11.2 billion. The stock has a 52-week-high of $101.88 and a 52-week-low of $44.58. CrowdStrike Holdings's stock last closed at $46.20 per share.
  • For Fiat Chrysler Automobiles NV (NYSE: FCAU), Exane BNP Paribas upgraded the stock from Neutral to Outperform. Fiat Chrysler Automobiles earned $0.88 in the third quarter, compared to $1.01 in the year-ago quarter. The total market value of Fiat Chrysler Automobiles's outstanding shares is at $30.2 billion. The stock has a 52-week-high of $17.46 and a 52-week-low of $12.11. Fiat Chrysler Automobiles's stock last closed at $16.11 per share.
  • Evercore ISI Group changed the rating for Live Nation Entertainment Inc (NYSE: LYV) from In-Line to Outperform. For the third quarter, Live Nation Entertainment had an EPS of $0.71, compared to year-ago quarter EPS of $0.70. The current market cap for Live Nation Entertainment is at $15.0 billion. The stock has a 52-week-high of $73.72 and a 52-week-low of $46.02. Live Nation Entertainment's stock last closed at $64.47 per share.
  • For PFSweb Inc (NASDAQ: PFSW), Lake Street upgraded the stock from Hold to Buy. PFSweb earned $0.02 in the third quarter, compared to $0.10 in the year-ago quarter. PFSweb's market cap stands at $48.3 million. The stock has a 52-week-high of $7.00 and a 52-week-low of $2.03. PFSweb's stock last closed at $3.40 per share.
  • For Rent-A-Center Inc (NASDAQ: RCII), Stifel Nicolaus upgraded the stock from Hold to Buy. In the third quarter, Rent-A-Center showed an EPS of $0.47, compared to $0.32 from the year-ago quarter. Rent-A-Center's market cap stands at $1.4 billion. The stock has a 52-week-high of $28.25 and a 52-week-low of $11.98. Rent-A-Center's stock last closed at $22.34 per share.
  • Stifel changed the rating for Rent-A-Center Inc (NASDAQ: RCII) from Hold to Buy. For the third quarter, Rent-A-Center had an EPS of $0.47, compared to year-ago quarter EPS of $0.32. Rent-A-Center's market cap stands at $1.4 billion. The stock has a 52-week-high of $28.25 and a 52-week-low of $11.98. Rent-A-Center's stock last closed at $22.34 per share.

 

Downgrades

  • JP Morgan changed the rating for Arch Capital Group Ltd (NASDAQ: ACGL) from Overweight to Neutral. Arch Capital Group earned $0.63 in the third quarter, compared to $0.59 in the year-ago quarter. Arch Capital Group's market cap stands at $16.9 billion. The stock has a 52-week-high of $42.86 and a 52-week-low of $24.79. Arch Capital Group's stock last closed at $40.79 per share.
  • RBC Capital downgraded the stock for Albemarle Corp (NYSE: ALB) from Outperform to Sector Perform. In the third quarter, Albemarle showed an EPS of $1.53, compared to $1.31 from the year-ago quarter. Albemarle's market cap stands at $6.4 billion. The stock has a 52-week-high of $103.37 and a 52-week-low of $58.63. Albemarle's stock last closed at $67.74 per share.
  • JP Morgan changed the rating for Amneal Pharmaceuticals Inc (NYSE: AMRX) from Neutral to Underweight. Amneal Pharmaceuticals earned $0.04 in the third quarter, compared to $0.28 in the year-ago quarter. The current market cap for Amneal Pharmaceuticals is at $959.2 million. The stock has a 52-week-high of $20.40 and a 52-week-low of $2.27. Amneal Pharmaceuticals's stock last closed at $2.64 per share.
  • JMP Securities downgraded the stock for Box Inc (NYSE: BOX) from Market Outperform to Market Perform. In the second quarter, Box showed an EPS of $0.00, compared to ($0.05) from the year-ago quarter. The current market cap for Box is at $2.4 billion. The stock has a 52-week-high of $24.93 and a 52-week-low of $12.46. Box's stock last closed at $16.44 per share.
  • For Craft Brew Alliance Inc (NASDAQ: BREW), Maxim Group downgraded the stock from Buy to Hold. For the third quarter, Craft Brew Alliance had an EPS of \ No EPS Value , compared to year-ago quarter EPS of $0.00. The total market value of Craft Brew Alliance's outstanding shares is at $158.0 million. The stock has a 52-week-high of $17.40 and a 52-week-low of $7.11. Craft Brew Alliance's stock last closed at $7.33 per share.
  • Baird changed the rating for Cellular Biomedicine Group Inc (NASDAQ: CBMG) from Outperform to Neutral. For the third quarter, Cellular Biomedicine Gr had an EPS of ($0.82), compared to year-ago quarter EPS of ($0.56). The total market value of Cellular Biomedicine Gr's outstanding shares is at $352.4 million. The stock has a 52-week-high of $20.63 and a 52-week-low of $10.98. Cellular Biomedicine Gr's stock last closed at $17.89 per share.
  • For CSX Corp (NASDAQ: CSX), Deutsche Bank downgraded the stock from Buy to Hold. For the third quarter, CSX had an EPS of $1.08, compared to year-ago quarter EPS of $1.05. The total market value of CSX's outstanding shares is at $54.1 billion. The stock has a 52-week-high of $80.73 and a 52-week-low of $58.47. CSX's stock last closed at $73.90 per share.
  • HSBC changed the rating for Eaton Corp PLC (NYSE: ETN) from Buy to Hold. For the third quarter, Eaton had an EPS of $1.52, compared to year-ago quarter EPS of $1.43. Eaton's market cap stands at $34.9 billion. The stock has a 52-week-high of $92.37 and a 52-week-low of $64.46. Eaton's stock last closed at $91.88 per share.
  • Barrington Research changed the rating for Fluent Inc (NASDAQ: FLNT) from Outperform to Market Perform. Fluent earned ($0.01) in the third quarter, compared to $0.06 in the year-ago quarter. The current market cap for Fluent is at $209.9 million. The stock has a 52-week-high of $7.47 and a 52-week-low of $2.26. Fluent's stock last closed at $2.54 per share.
  • ScotiaBank downgraded the stock for Hudbay Minerals Inc (NYSE: HBM) from Sector Perform to Sector Outperform. For the third quarter, Hudbay Minerals had an EPS of ($0.08), compared to year-ago quarter EPS of $0.09. The current market cap for Hudbay Minerals is at $1.3 billion. The stock has a 52-week-high of $7.83 and a 52-week-low of $2.99. Hudbay Minerals's stock last closed at $3.67 per share.
  • DA Davidson changed the rating for Heritage Financial Corp (NASDAQ: HFWA) from Buy to Neutral. In the third quarter, Heritage Financial showed an EPS of $0.48, compared to $0.42 from the year-ago quarter. Heritage Financial's market cap stands at $1.0 billion. The stock has a 52-week-high of $35.63 and a 52-week-low of $25.24. Heritage Financial's stock last closed at $28.69 per share.
  • BMO Capital downgraded the stock for OrganiGram Holdings Inc (NASDAQ: OGI) from Outperform to Market Perform. The current market cap for OrganiGram Holdings is at $710.5 million. The stock has a 52-week-high of $8.36 and a 52-week-low of $2.71. OrganiGram Holdings's stock last closed at $3.39 per share.

 

Initiations

  • SunTrust Robinson Humphrey initiated coverage on Alexion Pharmaceuticals Inc (NASDAQ: ALXN) with a Buy rating. The price target for Alexion Pharmaceuticals is set at $125.00. For the third quarter, Alexion Pharmaceuticals had an EPS of $2.79, compared to year-ago quarter EPS of $2.02. Alexion Pharmaceuticals's market cap stands at $21.6 billion. The stock has a 52-week-high of $141.86 and a 52-week-low of $92.56. Alexion Pharmaceuticals's stock last closed at $109.01 per share.
  • With a rating of Buy, SunTrust Robinson Humphrey initiated coverage on Amgen Inc (NASDAQ: AMGN). The price target is set at $256.00 for Amgen. Amgen earned $3.66 in the third quarter, compared to $3.69 in the year-ago quarter. The total market value of Amgen's outstanding shares is at $115.3 billion. The stock has a 52-week-high of $221.38 and a 52-week-low of $166.30. Amgen's stock last closed at $220.70 per share.
  • RBC Capital initiated coverage on Ares Capital Corp (NASDAQ: ARCC) with an Outperform rating. The price target for Ares Capital is set at $20.00. For the third quarter, Ares Capital had an EPS of $0.48, compared to year-ago quarter EPS of $0.45. The total market value of Ares Capital's outstanding shares is at $7.9 billion. The stock has a 52-week-high of $19.28 and a 52-week-low of $14.50. Ares Capital's stock last closed at $18.55 per share.
  • Deutsche Bank initiated coverage on Arlo Technologies Inc (NYSE: ARLO) with a Buy rating. The price target for Arlo Technologies is set at $4.00. For the third quarter, Arlo Technologies had an EPS of ($0.32), compared to year-ago quarter EPS of ($0.05). Arlo Technologies's market cap stands at $258.1 million. The stock has a 52-week-high of $13.71 and a 52-week-low of $2.66. Arlo Technologies's stock last closed at $2.68 per share.
  • SunTrust Robinson Humphrey initiated coverage on Biogen Inc (NASDAQ: BIIB) with a Buy rating. The price target for Biogen is set at $337.00. For the third quarter, Biogen had an EPS of $9.17, compared to year-ago quarter EPS of $7.40. The current market cap for Biogen is at $42.9 billion. The stock has a 52-week-high of $344.00 and a 52-week-low of $215.78. Biogen's stock last closed at $294.14 per share.
  • SunTrust Robinson Humphrey initiated coverage on Biomarin Pharmaceutical Inc (NASDAQ: BMRN) with a Buy rating. The price target for Biomarin Pharmaceutical is set at $110.00. For the third quarter, Biomarin Pharmaceutical had an EPS of $0.30, compared to year-ago quarter EPS of ($0.07). Biomarin Pharmaceutical's market cap stands at $13.1 billion. The stock has a 52-week-high of $100.13 and a 52-week-low of $62.88. Biomarin Pharmaceutical's stock last closed at $75.33 per share.
  • SunTrust Robinson Humphrey initiated coverage on BioXcel Therapeutics Inc (NASDAQ: BTAI) with a Buy rating. The price target for BioXcel Therapeutics is set at $24.00. BioXcel Therapeutics earned ($0.54) in the second quarter, compared to ($0.19) in the year-ago quarter. The current market cap for BioXcel Therapeutics is at $110.7 million. The stock has a 52-week-high of $12.00 and a 52-week-low of $2.41. BioXcel Therapeutics's stock last closed at $4.11 per share.
  • Stifel Nicolaus initiated coverage on Clarivate Analytics PLC (NYSE: CCC) with a Hold rating. The price target for Clarivate Analytics is set at $18.00. Clarivate Analytics earned $0.14 in the third quarter. The current market cap for Clarivate Analytics is at $5.1 billion. The stock has a 52-week-high of $17.80 and a 52-week-low of $12.70. Clarivate Analytics's stock last closed at $17.10 per share.
  • Goldman Sachs initiated coverage on Check Point Software Technologies Ltd (NASDAQ: CHKP) with a Neutral rating. The price target for Check Point Software Tech is set at $123.00. Check Point Software Tech earned $1.44 in the third quarter, compared to $1.38 in the year-ago quarter. Check Point Software Tech's market cap stands at $17.0 billion. The stock has a 52-week-high of $132.75 and a 52-week-low of $98.57. Check Point Software Tech's stock last closed at $115.87 per share.
  • JP Morgan initiated coverage on Conmed Corp (NASDAQ: CNMD) with an Overweight rating. The price target for Conmed is set at $136.00. For the third quarter, Conmed had an EPS of $0.62, compared to year-ago quarter EPS of $0.46. Conmed's market cap stands at $3.1 billion. The stock has a 52-week-high of $113.51 and a 52-week-low of $56.91. Conmed's stock last closed at $109.99 per share.
  • For Corteva Inc (NYSE: CTVA), Redburn initiated coverage, by setting the current rating at Buy. In the third quarter, Corteva showed an EPS of ($0.39), compared to ($0.60) from the year-ago quarter. The total market value of Corteva's outstanding shares is at $19.7 billion. The stock has a 52-week-high of $32.78 and a 52-week-low of $24.35. Corteva's stock last closed at $26.73 per share.
  • With a rating of Buy, SunTrust Robinson Humphrey initiated coverage on Fate Therapeutics Inc (NASDAQ: FATE). The price target is set at $25.00 for Fate Therapeutics. In the third quarter, Fate Therapeutics showed an EPS of ($0.40), compared to ($0.31) from the year-ago quarter. The current market cap for Fate Therapeutics is at $1.1 billion. The stock has a 52-week-high of $22.82 and a 52-week-low of $11.00. Fate Therapeutics's stock last closed at $14.50 per share.
  • With a rating of Neutral, Goldman Sachs initiated coverage on FireEye Inc (NASDAQ: FEYE). The price target is set at $18.00 for FireEye. For the third quarter, FireEye had an EPS of $0.02, compared to year-ago quarter EPS of $0.06. The total market value of FireEye's outstanding shares is at $3.4 billion. The stock has a 52-week-high of $20.51 and a 52-week-low of $12.66. FireEye's stock last closed at $17.12 per share.
  • With a rating of Buy, Goldman Sachs initiated coverage on Fortinet Inc (NASDAQ: FTNT). The price target is set at $113.00 for Fortinet. In the third quarter, Fortinet showed an EPS of $0.67, compared to $0.49 from the year-ago quarter. Fortinet's market cap stands at $13.9 billion. The stock has a 52-week-high of $98.21 and a 52-week-low of $64.41. Fortinet's stock last closed at $95.95 per share.
  • With a rating of Hold, SunTrust Robinson Humphrey initiated coverage on Gilead Sciences Inc (NASDAQ: GILD). The price target is set at $70.00 for Gilead Sciences. For the third quarter, Gilead Sciences had an EPS of $1.75, compared to year-ago quarter EPS of $1.84. The total market value of Gilead Sciences's outstanding shares is at $80.6 billion. The stock has a 52-week-high of $72.90 and a 52-week-low of $60.32. Gilead Sciences's stock last closed at $64.64 per share.
  • With a rating of Buy, SunTrust Robinson Humphrey initiated coverage on Momenta Pharmaceuticals Inc (NASDAQ: MNTA). The price target is set at $29.00 for Momenta Pharmaceuticals. Momenta Pharmaceuticals earned ($0.59) in the third quarter, compared to ($0.45) in the year-ago quarter. The total market value of Momenta Pharmaceuticals's outstanding shares is at $1.5 billion. The stock has a 52-week-high of $16.65 and a 52-week-low of $9.51. Momenta Pharmaceuticals's stock last closed at $16.00 per share.
  • With a rating of Buy, Bank of America initiated coverage on Oceaneering International Inc (NYSE: OII). The price target is set at $17.00 for Oceaneering International. Oceaneering International earned ($0.30) in the third quarter, compared to ($0.14) in the year-ago quarter. The total market value of Oceaneering International's outstanding shares is at $1.4 billion. The stock has a 52-week-high of $21.29 and a 52-week-low of $10.74. Oceaneering International's stock last closed at $14.02 per share.
  • With a rating of Buy, Goldman Sachs initiated coverage on Palo Alto Networks Inc (NYSE: PANW). The price target is set at $295.00 for Palo Alto Networks. For the fourth quarter, Palo Alto Networks had an EPS of $1.47, compared to year-ago quarter EPS of $1.28. The total market value of Palo Alto Networks's outstanding shares is at $19.7 billion. The stock has a 52-week-high of $260.63 and a 52-week-low of $160.08. Palo Alto Networks's stock last closed at $236.01 per share.
  • With a rating of Buy, SunTrust Robinson Humphrey initiated coverage on PTC Therapeutics Inc (NASDAQ: PTCT). The price target is set at $78.00 for PTC Therapeutics. PTC Therapeutics earned ($1.06) in the third quarter, compared to ($1.06) in the year-ago quarter. PTC Therapeutics's market cap stands at $2.5 billion. The stock has a 52-week-high of $48.81 and a 52-week-low of $27.53. PTC Therapeutics's stock last closed at $41.30 per share.
  • SunTrust Robinson Humphrey initiated coverage on Arcus Biosciences Inc (NYSE: RCUS) with a Buy rating. The price target for Arcus Biosciences is set at $20.00. For the third quarter, Arcus Biosciences had an EPS of ($0.51), compared to year-ago quarter EPS of ($0.25). The current market cap for Arcus Biosciences is at $359.9 million. The stock has a 52-week-high of $13.77 and a 52-week-low of $6.30. Arcus Biosciences's stock last closed at $7.60 per share.
  • With a rating of Hold, SunTrust Robinson Humphrey initiated coverage on Regeneron Pharmaceuticals Inc (NASDAQ: REGN). The price target is set at $360.00 for Regeneron Pharmaceuticals. In the third quarter, Regeneron Pharmaceuticals showed an EPS of $6.67, compared to $5.87 from the year-ago quarter. The total market value of Regeneron Pharmaceuticals's outstanding shares is at $33.6 billion. The stock has a 52-week-high of $442.00 and a 52-week-low of $271.37. Regeneron Pharmaceuticals's stock last closed at $344.28 per share.

Posted-In: Initiations top upgradesUpgrades Downgrades Initiation Intraday Update Analyst Ratings

 

Related Articles (ACGL + ALB)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
VIACJP MorganReinstates50.0
NUVASVB LeerinkMaintains92.0
SRPTCantor FitzgeraldMaintains211.0
SRPTPiperJaffrayMaintains210.0
LULUGoldman SachsMaintains219.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Got Milk? Dean Foods Files For Chapter 11 Bankruptcy

Roku's Earnings Exhibited Its Leadership Position